Alpha Cognition (ACOG) Stock: Buy, Sell, or Hold?
ACOG - Alpha Cognition Inc. Common Stock
$9.10
0.40 (4.60%)
▲
5d:
+7.44%
30d:
-2.31%
90d:
+15.19%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When ACOG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ACOG shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ACOG shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ACOG is currently trading at $9.10, which is considered fair relative to its 30-day fair value range of $8.66 to $9.32.
Technical Outlook: Technically, ACOG is in a strong uptrend. Immediate support is located at $8.30, while resistance sits at $9.43. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $18.00 (+97.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ACOG is in a strong uptrend. Immediate support is located at $8.30, while resistance sits at $9.43. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: The stock scores a mixed 48/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $18.00 (+97.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.66 -
$9.32
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
84.2%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (48/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.6%)
- BULLISH: Trading 97.8% below Wall St target ($18.00)
- NEUTRAL: Bottoming setup forming (48/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$8.66 -
$9.32
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.84
(9.3%)
Support & Resistance Levels
Support Level
$8.30
Resistance Level
$9.43
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-14.68
Wall Street Target
$18.00
(+97.8%)
Revenue Growth (YoY)
267.6%
Profit Margin
-137.7%
Share & Embed Analysis
Last updated: October 04, 2026 4:00 AM ET
Data refreshes hourly during market hours. Next update: 5:00 AM
Data refreshes hourly during market hours. Next update: 5:00 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACOG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 56 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$570 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$63 | 60 BUY |
